Get Rid of Your Double Chin FOREVER!
Also Tightens Any Loose Skin!
About SUBMENTAL FULLNESS
Patients asking about their submental fullness may, at times, refer to it as their “double chin.”
It is a common, yet undertreated facial aesthetic condition that can:
- Detract from an otherwise balanced and harmonious facial appearance1
- Lead to an older and heavier look2
- Impact a broad range of adults, including both women and men
- Be caused by aging, genetics and/or weight gain3
According to a 2015 survey by the American Society for Dermatologic Surgery (ASDS), 67% of consumers are bothered by submental fullness—nearly as many as those bothered by lines and wrinkles around the eyes (69%).4
KYBELLA® is the first and only FDA-approved injectable drug that contours and improves the appearance of submental fullness. KYBELLA® allows you to further expand your aesthetic injectable portfolio and offerings to your patients.
The number of injections and the number of treatments should be tailored to the individual patient’s submental fat distribution and treatment goals. Once the aesthetic response is achieved with KYBELLA®, retreatment is not expected.1
KYBELLA® is supplied in a pack of 4 single patient use 2 mL vials. KYBELLA® is administered by subcutaneous injections into submental fat in approximately 0.2 mL per injection spaced 1 cm apart using a 30G or smaller needle.
KYBELLA® is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. The safe and effective use of KYBELLA® has not been established outside the submental area and is not recommended.
Not all patients are candidates for KYBELLA®. Give careful consideration in patients with prominent platysmal bands or excessive skin laxity, who may not achieve aesthetically desirable results. Avoid use of KYBELLA® in patients who have current or prior history of dysphagia or causes of submental fullness other than submental fat. Caution should be used in patients who have had prior surgical or aesthetic treatment of the submental area.
KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.
The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.
Important Safety Information
KYBELLA® is contraindicated in the presence of infection at the injection sites.
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.
Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration site reactions, e.g., pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1-1.5 cm) to salivary glands, lymph nodes and muscles.
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema,and induration.
Report side effects to the FDA at 1-800-FDA-1088 or Allergan Medical Information at 800-433-8871.